FA involvement in the mechanism of action of celecoxib and E7123 in DLBCL cell lines. (A) Immunoblot analysis of FA proteins was performed in KARPAS-422, HT, and DB cells treated with vehicle (V) or 60μM of celecoxib or E7123 for 4, 8, 15, or 24 hours. Expression levels of FAK are not shown in DB cells because they were undetectable. Equal loading was ensured by immunoblotting against GAPDH. (B) Immunolocalization of p130Cas in HT and KARPAS-422 (K-422) cell lines after treatment with 60μM celecoxib (CX) or E7123 for the period times at which we observed up-regulation of the 31-kDa fragment by Western blot (4-8 hours for celecoxib and 1 hour for E7123). p130Cas was stained with anti-p130Cas-tetramethylrhodamine isothiocyanate antibody (red, second column), the nucleus was stained with Hoechst (green, first column), and colocalization was detected by merging (yellow, third column; original magnification ×630). Slides were viewed with an inverted microscope (Axiovert 200M). Images were acquired using a digital camera (Coolsnap; Photometrics) and processed with MetaMorph Version 5.01 software. (C) Molecular analysis of DB transfectants. Equal loading was checked by immunobloting against GAPDH. (D) Alteration of cell viability in infected cells (GFP, CASFL, and MyrFAK) after 4-hour exposure to the drug. The overexpression of wild-type p130Cas and active MyrFAK partially reverted the cytotoxic effect of celecoxib and E7123 in DB cells (Mann-Whitney U test): *P < .05; **P < .01. Error bars represent SE.